Cargando…
Validation of a Fast, Robust, Inexpensive, Two-Tiered Neonatal Screening Test algorithm on Dried Blood Spots for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease, in particular when applied at an early stage of progression. The genetic cause of SM...
Autores principales: | Strunk, Annuska, Abbes, Andre, Stuitje, Antoine R., Hettinga, Chris, Sepers, Eline M., Snetselaar, Reinier, Schouten, Jan, Asselman, Fay-Lynn, Cuppen, Inge, Lemmink, Henny, van der Pol, W. Ludo, Engel, Henk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510214/ https://www.ncbi.nlm.nih.gov/pubmed/33072980 http://dx.doi.org/10.3390/ijns5020021 |
Ejemplares similares
-
Quantification of disease progression in spinal muscular atrophy with muscle MRI—a pilot study
por: Otto, Louise A.M., et al.
Publicado: (2021) -
Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021) -
Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol
por: Ros, Leandra A. A., et al.
Publicado: (2023) -
Quantitative MRI of skeletal muscle in a cross‐sectional cohort of patients with spinal muscular atrophy types 2 and 3
por: Otto, Louise A.M., et al.
Publicado: (2020) -
Relative hyperventilation in non-ventilated patients with spinal muscular atrophy
por: Veldhoen, Esther S., et al.
Publicado: (2020)